Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics, and machine learning. The company is headquartered in Dallas, Texas.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-15.45M |
| Operating Margin | 0.00% |
| Return on Equity | -400.90% |
| Return on Assets | -74.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.25 |
| Price-to-Book | 9.74 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $12.78M |
| Float | $9.85M |
| % Insiders | 20.28% |
| % Institutions | 22.57% |
Volatility is currently expanding
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
DALLAS--(BUSINESS WIRE)--Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmark.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP‑284 to treat patients with mantle cell lymphoma (.
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.
DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers." The allowed claims cover methods of selecting and treating patients with ovar.
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational Biologist” persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LTRN and any ticker you trade — then tracks every position and per-strategy win rate.
